NeuroPace Reports Strong Q1 Results, Raises Full-Year Revenue Guidance, Progresses FDA Approval

summarizeSummary

NeuroPace announced strong first-quarter financial results, beating revenue expectations and raising its full-year guidance, while also making progress on a key FDA approval for market expansion.

check_boxKey Events

• Exceeded Q1 Revenue Guidance

  Reported total revenue of $22.1 million for Q1 2026, surpassing the high end of its previous guidance range of $21 million to $22 million.

• Raised Full-Year Revenue Guidance

  Increased full-year 2026 revenue guidance to $99 million-$101 million, up from the prior range of $98 million-$100 million, reflecting underlying RNS growth of 21% to 23%.

• Improved Adjusted EBITDA Outlook

  Adjusted EBITDA guidance for full-year 2026 was improved to a loss between ($8.5) million and ($9.5) million, compared to previous guidance of ($9.0) million to ($10.0) million.

• Progress on FDA Indication Expansion

  Completed the FDA mid-cycle review meeting for the NAUTILUS PMA supplement, consistent with the expected regulatory timeline for potential approval in mid-2026 for idiopathic generalized epilepsy (IGE).

auto_awesomeAnalysis

NeuroPace reported first-quarter revenue of $22.1 million, exceeding the high end of its previously issued guidance. The company also raised its full-year 2026 revenue guidance to $99 million-$101 million and improved its Adjusted EBITDA outlook. This positive financial performance is coupled with significant progress on the NAUTILUS PMA supplement for idiopathic generalized epilepsy (IGE) indication expansion, with a mid-cycle FDA review completed, indicating potential market expansion in mid-2026.